US0042251084
© BusinessWire
12.12.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is e...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time.
A live webcast of Acadia’s fireside chat will be accessible on the company’s website, acadia.com, under the investors section and an archived re...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025.
“Acadia delivered another strong quarter, generating total revenue of $278.6 million,” said Catherine Owen Adams, Chief Executive Officer. “NUPLAZID achieved record sales of $177.5 million representing a significant inf...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
28.10.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
UBS Global Healthcare Conference
Fireside Chat: Monday, November 10, 2025 at 2:00 p.m. Eastern Time in Palm Beach Gardens, FL
Jefferies Global Healthcare Conference in London
Presentation: Tuesday, November 18, 2025 at 8:30...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
22.10.2025
ACAD
LISTED
NASDAQ
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary duties to shareholders.
If you currently own Acadia stock and acquired shares on or before September 9, 2019, you may be able to seek corporate governance reforms, the retur...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
ACAD
LISTED
NASDAQ
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
News Preview
Equity Insider
News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, Oct. 21, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
ACAD
LISTED
NASDAQ
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
News Preview
Equity Insider
News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, Oct. 21, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
ACAD
LISTED
NASDAQ
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
News Preview
Equity Insider
News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, Oct. 21, 2025 /CNW/ -- Equ...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time.
The conference call will be availa...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson’s Disease and Movement Disorders® being held October 5-9, 2025, in Honolulu, Hawaii.
The presentations highlight updates from the company’s robust pipeline...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS). Intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2025
ACAD
LISTED
NASDAQ
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Developmental Medicine and Child Neurology published interim results from the caregiver-reported observational online, open-label, ongoing LOTUS study evaluating effectiveness and tolerability outcomes in patients with Rett syndrome who are prescribed DAYBUE® (trofinetide)...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
08.09.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 4, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 161,676 shares of common stock and 49,363 restricted stock units (“RSUs”) to eighteen new employees under A...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:
Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat: Monday, September 8, 2025 at 10:45 a.m. Eastern Time in New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Fireside Chat: Tuesday,...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Konstantina (“Tina”) Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia’s business development and corporate strategy and serve as a member of the Company’s Executive Leadership Team, reporting to Catherine Owen A...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 6, 2025, at 4:30 p.m. Eastern Time.
The webcast will be available on Acadia’s...
Themefolio
Profiler
Peergroup
© BusinessWire
03.07.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 35,607 shares of common stock and 29,571 restricted stock units (“RSUs”) to seventeen new employees under Acadia...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth.
Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or...
Themefolio
Profiler
Peergroup
© BusinessWire
17.06.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 187,664 shares of common stock and 89,582 restricted stock units (“RSUs”) to forty one new employees under Acadi...
Themefolio
Profiler
Peergroup
© BusinessWire
09.06.2025
ACAD
LISTED
NASDAQ
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia’s litigation again...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET.
The event will feature members of Acadia’s management team and R&D organization, key opinion leaders (KOL) and members of the caregiver commun...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 4:00 p.m. Eastern Time.
A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and a...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia’s commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 7, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 64,252 shares of common stock and 56,277 restricted stock units (“RSUs”) to twenty-eight new employees under Acad...
Themefolio
Profiler
Peergroup
© BusinessWire
16.05.2025
ACAD
LISTED
NASDAQ
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In today’s order, the Court ruled in favor of Acadia on both infringement...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2025.
“2025 is off to a strong start for Acadia, achieving total revenue of $244.3 million in the first quarter,” said Catherine Owen Adams, Chief Executive Officer. “DAYBUE has achieved meaningful patient growth for the first ti...
Themefolio
Profiler
Peergroup
© BusinessWire
05.05.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 3:40 p.m. Pacific Time.
A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time.
The webcast will be available on Acadia’s website,...
Themefolio
Profiler
Peergroup
© BusinessWire
11.04.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 172,637 shares of common stock and 64,791 restricted stock units (“RSUs”) to twenty-two new employees under Aca...
Themefolio
Profiler
Peergroup
© BusinessWire
14.03.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units (“RSUs”) to thirteen new employees under Acadia...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences:
UBS Virtual CNS Day 2025
Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time
Stifel 2025 Virtual CNS Forum
Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time
24th Annual Needham Virtual...
Themefolio
Profiler
Peergroup
© BusinessWire
05.03.2025
ACAD
LISTED
NASDAQ
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar s...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study (EUCT: 2024-514514-12-00) of ACP-711, formerly SAN711, in healthy volunteers.
In the study, ACP-711 was safe and generally well tolerated across al...
Themefolio
Profiler
Peergroup
© BusinessWire
27.02.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 11:10 a.m. Eastern Time.
A live webcast of Acadia’s fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archiv...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024.
“We closed 2024 on a strong note with each of our brands achieving record revenues in the fourth quarter and well-positioned for continued growth in 2025,” said Catherine Owen Adams, Chief Executive Offic...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 6, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 171,065 shares of common stock and 55,170 restricted stock units (“RSUs”) to eighteen new employees under Ac...
Themefolio
Profiler
Peergroup
© BusinessWire
12.02.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on February 26, 2025, at 4:30 p.m. Eastern Time.
The webcast will...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on January 13, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,782 shares of common stock and 13,928 restricted stock units (“RSUs”) to twelve new employees under Acadi...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
“2025 is shaping...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing authorization, trofinetide will be the firs...
Themefolio
Profiler
Peergroup
© PR Newswire
30.12.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Set to Join S&P SmallCap 600
News Preview
NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE: SSB) is acquiring Independent Bank Group in a deal expected...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time.
A live webcas...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 38,568 shares of common stock and 22,264 restricted stock units (“RSUs”) to thirteen new employees under Aca...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. As described at the time the agreement to sell was announced on November 5, 2024, Acadia is required to pay Neuren Pharmaceuticals Limited one-third of the net pro...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. The first indication the Company plans to pursue is development of SAN711...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
Citi's 2024 Global Healthcare Conference
Fireside Chat: Tuesday, December 3, 2024 at 10:15 a.m. Eastern Time in Miami, FL
7th Annual Evercore HealthCONx Conference
Fireside Chat: Wednesday, December 4, 2024 at 2:35 p.m. Eas...
Themefolio
Profiler
Peergroup
© BusinessWire
15.11.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 70,571 shares of common stock and 40,731 restricted stock units (“RSUs”) to twenty-three new employees under...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.
“The success of Acadia’s two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive mileston...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of D...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 6, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operation...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older under the Priority Review process. The Notice of Compliance authorization of DAYBUE makes it the first and only drug...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on October 3, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,631 shares of common stock and 30,484 restricted stock units (“RSUs”) to thirteen new employees under Aca...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 23, 2024, the Board of Directors granted Catherine Owen Adams, Acadia’s new Chief Executive Officer, a one-time sign-on equity award of (i) 353,261 options to purchase shares of Acadia’s common stock with an exercise price of $16.29 per share, Acadia’s closing trading pri...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
ACAD
LISTED
NASDAQ
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors.
“We are excited to welcome Catherine Owen Adams as the new CEO of Acadia,” said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. “Catherine is a prov...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
ACAD
LISTED
NASDAQ
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
News Preview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside Chat: Wednesday, September 4, 2024 at 4:50 p.m. Eastern Time in New York, NY
Baird 2024 Global Healthcare Conference
Fireside Chat: Wednesday, September 11, 2...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2024
ACAD
LISTED
NASDAQ
Ryan Reynolds Announces More to Parkinson’s® Campaign
News Preview
Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Pa...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
